We have located links that may give you full text access.
Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis.
Rheumatology 2022 November 29
Dealing with patients with both multiple sclerosis (MS) and inflammatory rheumatic disorders (IRD) is not uncommon for a rheumatologist, as there is a statistical association between spondyloarthritis and MS. As several central nervous system demyelinating events have been reported in patients treated with TNFi, the pre-existing demyelinating disease was considered a contraindication for TNFi. However, this contraindication is mainly based on a randomized controlled trial in MS and not on large epidemiologic studies. According to the last epidemiologic studies, TNFi might not be inducer of MS. Moreover, there are no clear recommendations on the use of the other DMARDs in patients suffering from an IRD and MS. In this review, we summarize the link between MS and the IRD and the impact of DMARDs on MS, especially TNFi. We also look at the impact of disease-modifying drugs for adults with MS on IRD.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app